Pivikto (Alpelisib) Tablet

Description

Description

This page contains brief details about the drug alpelisib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Alpelisib is an anticancer medication which was approved for its medical use on 24th May 2019.

Mechanism of Action of Alpelisib

Alpelisib is a targeted drug therapy for cancer that comes under the class of kinase inhibitors. It acts against the mutation of PI3K genes. PI3K genes are abundant in hormone receptor positive and human epidermal growth factor receptor 2 (HER2) breast cancers. Alpelisib works by stopping the cell signalling of PI3K genes and inhibits the growth and spread of cancer cells. It is often administered in combination with other chemotherapy agents like Fulvestrant.

Uses of Alpelisib

Alpelisib Tablet has been developed to treat advanced and metastatic breast cancer in men and menopausal women who have stopped responding to other treatments. It is particularly effective against hormone receptor positive and human epidermal growth factor receptor 2 (HER2) breast cancers caused by mutation in the PIK3CA gene.

Alpelisib Dosage available

Alpelisib is available as a film-coated tablets in the doses 150mg, 200mg, 200+50mg. Swallow the tablet whole with a glass of water without crushing or chewing them.